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Background: Russian ProMED-mail (ProMED-RUS) is one of
ProMED’s regional networks that offers Russian language reports
on emerging infections in 15 Former Soviet Union (FSU) countries.
Several FSU countries have annual cases of Crimean-Congo hemor-
rhagic fever (CCHF).
We wanted to review ProMED-RUS data to assess the epidemi-
ology in the territory of FSU.
Methods & Materials: We used CCHF as the keyword to search
reports in ProMED-RUS posted from 2005 to 2015. Comments by
the moderators to complement the information provided in the
outbreak itself were also reviewed.
Results: According to ProMED-RUS, CCHFwere recorded inRus-
sia, Kazakhstan, Georgia, Tajikistan, and Uzbekistan. The South
of Russia (Stavropol, Rostov, Volgograd and Astrakhan regions,
Kalmikiya, Ingushetiya, Dagestan, Karachaevo-Cherkessia) are
endemic for CCHF. Between the years 2005 and 2015, 1,397 total
cases, including 42 fatalities and a case fatality rate (CFR) of 4.2%
were recorded. The highest numberswere registered between 2006
and 2008, which coincides with ofﬁcial Russian MOH statistics.
Beginning in 2009, the incidence rate decreased, averaging 70 reg-
istered cases. In 2015 for the ﬁrst time since 2009, the number
of cases rose signiﬁcantly and reached up to 139. ProMED-RUS
reported about CCHF in Kazakhstan since 2008, with the highest
number of cases (26) in 2009 in the southern regions - Jambyl and
Kizilorda. Until 2015, 74 total cases and 16 fatal cases were reg-
istered with a CFR of 21.6% . In Tajikistan, ProMED-RUS reported
about 5 cases in 2009 including 3 fatalities, CFR - 60%. ProMED-
RUS published Georgia cases in 2012-2015: 2012 (1 case), 2013 (13
cases), 2014 (20 cases with 4 fatalities, CFR 20%) and this year 2
cases. In 2015 ProMED-RUS reported 13 CCHF cases in Uzbekistan
within 2013-2015, including 10 fatal cases.
CCHF starts inApril, peaks betweenMayand June, anddecreases
in August mostly due to tick bites. However, Kazakhstan (2009),
Tajikistan (2009), and Russia (2011) registered 3 nosocomial clus-
ters among healthcareworkers due to inadequate infection control
with 5, 7, and 9 cases respectively.
Conclusion: ProMED-RUS reports of outbreaks and comments
from experts provide useful information for emerging infection
case reporting, analysis, and comparison in the territory of FSU.
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Clinical features and likely predictors of
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Background: Early diagnosis of severe dengue is essential to
reduce morbidity and mortality from the illness. The aim of our
study was to evaluate clinical and laboratory indicators of severity
and mortality in hospitalized dengue cases.
Methods & Materials: This was a 2-yr (2012-2014) retrospec-
tive study of all in-patients fulﬁlling the WHO diagnostic criteria
of dengue . Clinical characteristics, laboratory parameters and
treatment modalities were evaluated with respect to severity and
mortality. Statistical analysis included c2 test for categorical vari-
ables and Student’s t –test for continuous variables.
Results: Of the 550 ‘probable’ dengue inpatients over the study
period, 126 were ‘severe dengue’, 364 were ‘dengue without warn-
ing signs’ and 60 were ‘dengue with warning signs (2009 WHO
classiﬁcation). Review of 21 fatalities, revealed that 48% (10/21)
were between 40 to 60 years old.11 of the fatal cases, had a Charl-
son comorbidity score > 3 (p=0.003). Bacterial coinfections had
a signiﬁcant association with mortality (7/21, p=0.002). Among
the presenting symptoms, fever > 7 days, headache, rash, aches
and pains, lethargy, restlessness and bleeding were signiﬁcantly
associated with fatality (p <0.05). Additionally hypoproteinemia,
hypotension on admission correlated signiﬁcantly with poor out-
come. Older age (> 60 yrs) was signiﬁcantly associated with severe
dengue (p=0.001) as was smoking and alcohol (p<0.05). Hem-
orrhagic manifestations, thrombocytopenia, pleural effusion and
ascites had signiﬁcant association with severe dengue (p<0.05).
Detailed review of hemogram revealed that leucocytosis (WBC
>10 K/cmm), lymphopenia (<20%) were associated with severity
(p=0.0051) and fatality (p=0.000086). Hemoglobin less than 12
g/dl had a statistical correlation with severe dengue (p=0.0092)
. Hematocrit > 46% was signiﬁcantly associated with both sever-
ity (p=0.004) and fatality (p=0.045). Remarkably inﬂammatory
markers like Neutrophil lymphocyte ratio of <5 on admission
was signiﬁcantly associated with severe dengue (p=0.003) and
mortality (p=0). Admission RDW platelet ratio of < 0.12 and lym-
phocyte monocyte ratio <0.12 were both associated signiﬁcantly
with severity and fatality. Elevated urea and creatinine were asso-
ciated signiﬁcantly with severity and mortality(p<0.05).
Conclusion: Our observations highlight simple clinical and lab-
oratory correlates of dengue severity and fatality. These could help
clinicians recognise and aggressivelymanage the high risk patients
to improve outcomes and morbidity.
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